Transcriptomic analysis of mammary tumor biospy from MMTV-ErbB2 transgenic mice [Docetaxlel]. Transcriptomic analysis of mammary tumor biospy from MMTV-ErbB2 transgenic mice [Docetaxlel]

The tyrosine kinase ErbB2 positive breast tumors have more aggressive tumor growth, poorer clinical outcome, and more resistance to radiotherapy, chemotherapy and hormone therapy. To identify the biomarkers for predicting the responses to chemotherapy, we treated genetically diverse F1 backcross (F1Bx) mice between C57BL/6J and FVB/N MMTV-Erbb2 transgenic mice with mammary tumor by docetaxel. Biopsies were taken in sterile conditions and processed for RNA and histological analysis before treatment. This will help us to have a better understanding of the heterogeneous response to chemotherapy and permit us to design better and more individualized (personalized) treatment strategies for human ErbB2 positive breast cancer. Overall design: 50 MMTV-ErbB2 mammary tumor biopsy before treatment were analyzed by Affymetrix microarrays.

酪氨酸激酶ErbB2阳性乳腺肿瘤具有更强的侵袭性生长特性、更差的临床预后，且对放疗、化疗及激素治疗的耐药性更高。为鉴定可预测化疗应答的生物标志物，本研究以携带乳腺肿瘤的C57BL/6J与FVB/N MMTV-ErbB2转基因小鼠为亲本，构建遗传多样性F1回交（F1Bx）小鼠模型，并对其施以多西他赛干预。研究人员于治疗前在无菌条件下采集活检样本，用于RNA分子检测与组织学分析。本研究将有助于深入阐明化疗应答的异质性机制，并可为人类ErbB2阳性乳腺癌制定更优化、更具个体化（个性化）的治疗策略提供科学依据。实验整体设计：采用Affymetrix基因微阵列，对50份治疗前的MMTV-ErbB2阳性乳腺肿瘤活检样本进行分析。